199 results on '"Bolwell, B. J."'
Search Results
2. Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma
3. Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation
4. Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients
5. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies
6. Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation
7. Quality of life and outcomes in patients ≥ 60 years of age after allogeneic hematopoietic cell transplantation
8. Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients
9. Effects of spleen status on early outcomes after hematopoietic cell transplantation
10. Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial
11. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia
12. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab
13. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia
14. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation
15. Ethical reasoning about patient eligibility in allogeneic BMT based on psychosocial criteria
16. 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation
17. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research
18. Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation
19. Allogeneic hematopoietic cell transplantation for metastatic breast cancer
20. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma
21. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies
22. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
23. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors
24. Allogeneic BMT and patient eligibility based on psychosocial criteria: a survey of BMT professionals
25. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival
26. High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia
27. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection
28. Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: can we safely transplant patients with impaired ejection fraction?
29. Are predictive factors clinically useful in bone marrow transplantation?
30. Syngeneic graft-versus-host disease: a report of two cases and literature review
31. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation
32. Transfusing platelets 2 h after the completion of amphotericin-B decreases its detrimental effect on transfused platelet recovery and survival
33. The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization.
34. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation.
35. Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
36. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy.
37. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin’s lymphoma.
38. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial.
39. Progressive disease after ABMT for Hodgkin’s disease.
40. Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count.
41. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4–9 involved axillary lymph nodes.
42. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation.
43. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase.
44. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.
45. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.
46. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group.
47. Routine cultures of bone marrow and peripheral stem cell harvests: clinical impact, cost analysis, and review.
48. A simplified method of CD34+ cell determination for peripheral blood progenitor cell transplantation and correlation with clinical engraftment.
49. A 68-year-old woman with high serum protein and no symptoms.
50. Outpatient bone marrow harvesting.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.